Dr. Dan Zekzer joined Frezent in 2022. Dr. Zekzer is currently an advisor for business development at multiple biotech and pharmaceutical companies including Frezent, UBE Corporation, and YYZ Pharmatech, and an interim CEO at a medical device company, EmbryoDx Solutions. He also serves as a Scientific Analyst at the Global Source Venture VC firm. Dr. Zekzer brings more than 20 years of experience in business development in pharmaceutical space, working as a Senior Director at Novo Nordisk and as the Director of Research Planning at Daiichi Sankyo Research Institute. He has an in-depth understanding of emerging trends in the pharmaceutical and biotech industries, and a proven track record in guiding strategic partnerships